Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APVO210 in Healthy Subjects and Patients with Psoriasis or Ulcerative Colitis
NCT03768219Phase 1Terminated
- Sponsor
- Aptevo Therapeutics
- Start
- Mar 2019
- Primary completion
- Jun 2020
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of APVO210 in psoriasis and ulcerative colitis (UC) (14 cohorts), sponsored by Aptevo Therapeutics. Primary endpoints: Number of subjects with adverse events at Day 141, Number of subjects with clinically relevant findings in vital signs at Day 141 and 3 more. Started Mar 2019; status: terminated.
02
Drugs
APVO210
03
Conditions
psoriasisulcerative colitis (UC)
Beyond the preview
Go deeper on NCT03768219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03768219.